Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is well positioned to capitalize on its diverse clinical pipeline, particularly with its lead candidate, taletrectinib, showing strong promise in the treatment of ROS1+ non-small cell lung cancer. With multiple product candidates in different stages of development and a strong cash position, management has the resources to continue expanding its pipeline. In addition, the company's recent acquisition of Japan rights to safusidenib could significantly expand its market potential and contribute to future revenue growth. Overall, Nuvation Bio's differentiated approach to addressing unmet needs in oncology makes it a compelling investment opportunity.

Bears say

Nuvation Bio is a speculative investment given its dependence on the success of its first commercial launch, Ibtrozi, for revenue and the potential for positive safety and efficacy differentiators. The company's potential upside lies in its pipeline, but its near-term commercialization risk is a major factor in maintaining a "Speculative Risk" rating.

Nuvation Bio (NUVB) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 9 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.